Valerio Therapeutics Société anonyme (0NWK.L)

0.1229 -0.1496 (-54.90%) At close: 06:55PM BST

Valerio Therapeutics Société anonyme

49, Bd du Général Martial Valin
Paris 75015
France
33 1 45 58 76 00
https://valeriotx.com

Sector(s): 
Industry: 
Full-time employees: 39

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Shefali Agarwal M.D., MPH	President, CEO & Chairwoman	N/A	N/A	1973
Ms. Joyce Carey	Executive Director of Finance and Head of FP&A	N/A	N/A	N/A
Ms. Robin Sutherland	VP & Global Head of Human Resources	N/A	N/A	N/A
Mr. Michel Forest	Chief Pharmacist & Quality Assurance Director	N/A	N/A	N/A
Ms. Huiping Jiang	Senior Vice President of Regulatory Affairs & Quality Assurance	N/A	N/A	N/A
Mr. Wael Jdey Ph.D.	Head of Preclinical	N/A	N/A	N/A
Dr. Donna Cabral-Lilly Ph.D.	VP & Head of CMC	N/A	N/A	N/A
Ms. Pam Slatcher	Head of Global PV	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Corporate governance

Valerio Therapeutics Société anonyme’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.